Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

TriSalus Life Sciences (TLSIW) Notes Payables (2022 - 2023)

Historic Notes Payables for TriSalus Life Sciences (TLSIW) over the last 2 years, with Q2 2023 value amounting to $1.6 million.

  • TriSalus Life Sciences' Notes Payables rose 6665.49% to $1.6 million in Q2 2023 from the same period last year, while for Jun 2023 it was $1.6 million, marking a year-over-year increase of 6665.49%. This contributed to the annual value of $944000.0 for FY2022, which is N/A changed from last year.
  • Latest data reveals that TriSalus Life Sciences reported Notes Payables of $1.6 million as of Q2 2023, which was up 6665.49% from $1.4 million recorded in Q1 2023.
  • TriSalus Life Sciences' 5-year Notes Payables high stood at $1.6 million for Q2 2023, and its period low was $809000.0 during Q1 2022.